4.62
Hcw Biologics Inc stock is traded at $4.62, with a volume of 58,719.
It is up +7.44% in the last 24 hours and down -52.76% over the past month.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
See More
Previous Close:
$4.30
Open:
$4.42
24h Volume:
58,719
Relative Volume:
0.03
Market Cap:
$5.51M
Revenue:
$6.59M
Net Income/Loss:
$-18.12M
P/E Ratio:
-0.4883
EPS:
-9.4605
Net Cash Flow:
$-11.45M
1W Performance:
-12.10%
1M Performance:
-52.76%
6M Performance:
-35.83%
1Y Performance:
-81.03%
Hcw Biologics Inc Stock (HCWB) Company Profile
Name
Hcw Biologics Inc
Sector
Industry
Phone
954-842-2024
Address
2929 N COMMERCE PKWY, MIRAMAR
Compare HCWB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
HCWB
Hcw Biologics Inc
|
4.62 | 5.96M | 6.59M | -18.12M | -11.45M | -9.4605 |
|
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hcw Biologics Inc Stock (HCWB) Latest News
HCW Biologics (HCWB) clears $2.8M disputes and $1.1M lien - Stock Titan
HCW Biologics Inc.: Top Mutual Funds Holders | QNCX | US40423R3030 - marketscreener.com
HCW Biologics Inc.: Fundamental Analysis and Financial Ratings | QNCX | US40423R3030 - marketscreener.com
HCW Biologics Inc.: Dividend historical data and projections - marketscreener.com
HCW Biologics regains Nasdaq compliance, plans stock split - Investing.com UK
HCW Biologics to Implement 1-for-6 Reverse Stock Split - Moomoo
HCW Biologics regains Nasdaq compliance, plans stock split By Investing.com - Investing.com Nigeria
HCW Biologics (NASDAQ: HCWB) regains bid-price compliance and sets 1-for-6 reverse split - Stock Titan
HCW Biologics Regains Nasdaq Bid Price Compliance and Announces 1-for-6 Reverse Stock Split - Quiver Quantitative
HCW Biologics clears Nasdaq bid-price rule, then splits stock 1-for-6 - Stock Titan
HCW BIOL: Target Price Consensus and Analysts Recommendations | HCWB | US40423R2040 - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
HCW Biologics Inc (HCWB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
HCW Biologics executes 1-for-6 reverse stock split for Nasdaq By Investing.com - Investing.com Australia
HCW Biologics Inc (HCWB) Stock Price, Quote, News & History - Benzinga
HCW Biologics' Reverse Split: A Calculated Gamble to Secure Its Future - BriefGlance
HCW Biologics executes 1-for-6 reverse stock split for Nasdaq - Investing.com
HCW Biologics Announces 1-for-6 Reverse Stock Split to Maintain Nasdaq Listing Compliance Effective June 30, 2026 - Minichart
HCW Biologics Announces 1-for-6 Reverse Stock Split - TipRanks
HCW Biologics (NASDAQ: HCWB) enacts 1-for-6 reverse split to support Nasdaq bid-price compliance - Stock Titan
HCW Biologics Inc (HCWB) Valuation: PE, PB & Fair Value Analysis - TradingKey
HCW Biologics, Inc. Actuals & Estimates (NASDAQ:HCWB) - TradingView
HCW Biologics Inc (HCWB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026 - Sahm
MSN Money - MSN
[EFFECT] HCW Biologics Inc. SEC Filing - Stock Titan
HCW Biologics Inc (HCWB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HCW Biologics Inc (HCWB) Institutional Confidence - TradingKey
HCW Biologics (HCWB) files exhibits-only S-1 amendment with new exhibits - Stock Titan
HCW Biologics Inc (HCWB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
HCW Biologics Inc (HCWB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
HCW Biologics Inc (HCWB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
HCW Biologics Inc (HCWB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
HCW Biologics Shareholders Approve Governance and Capital Measures - The Globe and Mail
HCW Biologics takes back rights to commercial-ready reagents - MSN
HCW Biologics reports positive early alopecia trial data - grafa.com
What's Going On With HCW Biologics Stock Tuesday?HCW Biologics (NASDAQ:HCWB) - Benzinga
HCWB: Preliminary Results from HCW Biologics' Phase 1 Trial Show Promising Data - GuruFocus
HCW Biologics reports positive early data for autoimmune drug By Investing.com - Investing.com Australia
HCW Biologics reports positive early data for autoimmune drug - Investing.com
HCW Biologics Announces Positive Results for Preliminary - GlobeNewswire
HCW Biologics Inc. Files Form 8-K with SEC Detailing Company and Stock Information - Minichart
HCW Biologics (HCWB) AGM 2026 Summary - Quartr
Shareholders back HCW Biologics (NASDAQ: HCWB) 2026 board slate - Stock Titan
HCW Biologics Inc Stock Short Interest Rises to 58.43% - Quiver Quantitative
HCWB Announces Selling Shareholder Plans for 5.69M Shares - GuruFocus
HCW Biologics Registers Resale of Up to 5.7 Million Shares - marketscreener.com
HCW Biologics Proposed Resale Of Up To 5.69 Million Shares Of Common Stock - TradingView
HCW Biologics (HCWB) files S-1 for resale of 5.69M PIPE shares and warrants - Stock Titan
Hcw Biologics Inc Stock (HCWB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Hcw Biologics Inc Stock (HCWB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GARRETT SCOTT T | Director |
May 22 '26 |
Buy |
1.41 |
177,936 |
250,000 |
203,441 |
| Byam Rebecca | Chief Financial Officer |
May 22 '26 |
Buy |
1.41 |
14,235 |
20,000 |
57,245 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):